- Home
- BLDP vs URGN Comparison
BLDP vs URGN Comparison
Compare BLDP & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLDP
- URGN
- Stock Information
- Founded
- BLDP 1979
- URGN 2004
- Country
- BLDP Canada
- URGN United States
- Employees
- BLDP N/A
- URGN N/A
- Industry
- BLDP Industrial Machinery/Components
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- BLDP Energy
- URGN Health Care
- Exchange
- BLDP Nasdaq
- URGN Nasdaq
- Market Cap
- BLDP 488.0M
- URGN 465.9M
- IPO Year
- BLDP 1995
- URGN 2017
- Fundamental
- Price
- BLDP $1.52
- URGN $10.19
- Analyst Decision
- BLDP Hold
- URGN Strong Buy
- Analyst Count
- BLDP 11
- URGN 5
- Target Price
- BLDP $2.25
- URGN $44.50
- AVG Volume (30 Days)
- BLDP 9.9M
- URGN 487.3K
- Earning Date
- BLDP 03-10-2025
- URGN 03-13-2025
- Dividend Yield
- BLDP N/A
- URGN N/A
- EPS Growth
- BLDP N/A
- URGN N/A
- EPS
- BLDP N/A
- URGN N/A
- Revenue
- BLDP $91,962,000.00
- URGN $89,363,000.00
- Revenue This Year
- BLDP N/A
- URGN $12.21
- Revenue Next Year
- BLDP $26.95
- URGN $46.19
- P/E Ratio
- BLDP N/A
- URGN N/A
- Revenue Growth
- BLDP 24.01
- URGN 15.64
- 52 Week Low
- BLDP $1.23
- URGN $9.78
- 52 Week High
- BLDP $3.66
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- BLDP 41.19
- URGN 38.51
- Support Level
- BLDP $1.55
- URGN $10.12
- Resistance Level
- BLDP $1.68
- URGN $10.91
- Average True Range (ATR)
- BLDP 0.13
- URGN 0.56
- MACD
- BLDP -0.04
- URGN -0.01
- Stochastic Oscillator
- BLDP 1.75
- URGN 20.71
About BLDP Ballard Power Systems Inc.
Ballard Power Systems Inc is a world leader in proton-exchange membrane fuel cells, power system development, and commercialization. The company's principal business is the design, development, manufacture, sale, and service of PEM fuel cell products for a variety of applications, focusing on power product markets of heavy-duty motive (bus, truck, rail, and marine applications), material handling, and stationary power generation. Sales are concentrated in the US, Europe, and China.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.